SMARCAL1 and central nervous system cancer: According to the findings of the Cox assessment (Fig. 2A and Additional file 1: Fig. S1), SMARCAL1 is identified as an adverse predictor of overall survival (OS) in Glioma, LUAD, and LIHC (P < 0.05), but exhibits potential as a beneficial factor in KIRC (P < 0.05).